Tsai B S, Watt G, Koesnadi K, Townley R G
Clin Allergy. 1984 Jul;14(4):363-71. doi: 10.1111/j.1365-2222.1984.tb02217.x.
Glucocorticoid hormones, which are widely used in the treatment of asthma, have been shown to potentiate physiological and biochemical beta-adrenergic responsiveness in asthmatics. These effects are presumably mediated through glucocorticoid receptors. In order to better understand glucocorticoid pharmacology in asthmatics, we assayed glucocorticoid receptors by directly binding a radioactively labelled glucocorticoid hormone, dexamethasone, to intact lymphocytes prepared from the peripheral blood of asthmatics and control subjects. Binding studies were performed with dexamethasone at 100 nM and 5 nM concentrations. At 100 nM dexamethasone, the mean number of lymphocyte glucocorticoid receptors (per cell) in control subjects (7191 +/- 385, n = 9) was not significantly different from that in asthmatic subjects (7772 +/- 437, n = 9). At 5 nM dexamethasone, the mean number of glucocorticoid receptors in control subjects (1177 +/- 194, n = 5) was not significantly different from that in asthmatic subjects (1215 +/- 108, n = 8). At 100 nM dexamethasone, males had significantly more receptors (7939 +/- 360, n = 11) than females (6764 +/- 72, n = 7). Our results suggest that the number of lymphocyte glucocorticoid receptors and the apparent affinity of dexamethasone for receptors are not related to the presence of severity of asthma; however, a significant sex effect exists which should be corrected for in future studies of lymphocyte glucocorticoid receptors.
糖皮质激素被广泛用于治疗哮喘,已被证明可增强哮喘患者生理和生化方面的β-肾上腺素能反应性。这些作用可能是通过糖皮质激素受体介导的。为了更好地了解哮喘患者的糖皮质激素药理学,我们通过将放射性标记的糖皮质激素地塞米松直接与从哮喘患者和对照受试者外周血中制备的完整淋巴细胞结合,来测定糖皮质激素受体。在地塞米松浓度为100 nM和5 nM的情况下进行结合研究。在地塞米松浓度为100 nM时,对照受试者(7191±385,n = 9)淋巴细胞糖皮质激素受体的平均数量(每细胞)与哮喘受试者(7772±437,n = 9)相比无显著差异。在地塞米松浓度为5 nM时,对照受试者(1177±194,n = 5)糖皮质激素受体的平均数量与哮喘受试者(1215±108,n = 8)相比无显著差异。在地塞米松浓度为100 nM时,男性的受体数量(7939±360,n = 11)显著多于女性(6764±72,n = 7)。我们的结果表明,淋巴细胞糖皮质激素受体的数量以及地塞米松对受体的表观亲和力与哮喘的存在或严重程度无关;然而,存在显著的性别效应,在未来淋巴细胞糖皮质激素受体的研究中应予以校正。